- $9.77bn
- $9.55bn
- $507.44m
Brief: Glaukos Q4 Sales USD 143 Million Vs. IBES Estimate USD 131.2 Million
U.S. RESEARCH ROUNDUP- Alphabet, Boeing, KLA
Medical device maker Glaukos posts smaller-than-expected loss in Q3 on strong demand in U.S.
U.S. STOCKS ON THE MOVE-Arm Holdings, silver miners, Zions Bancorp
U.S. STOCKS ON THE MOVE-Apple, Zoom, Arm Holdings
U.S. STOCKS ON THE MOVE-Glaukos, Reddit, Micron
Glaukos rise as US FDA clears eye therapy for rare corneal disease
US FDA approves Glaukos' new eye therapy (updated)
US FDA approves Glaukos' new eye therapy
U.S. RESEARCH ROUNDUP-Equinix, Fair Isaac, Meta
Glaukos Corp reports results for the quarter ended June 30 - Earnings Summary
Glaukos beats Q2 sales estimates, raises 2025 guidance
U.S. STOCKS ON THE MOVE-American Battery Technology, News Corp, National Fuel Gas
Glaukos slips after Medicare proposes cuts to eye surgery reimbursements
Brief: Glaukos Announces EU MDR Certification For iStent infinite And Other Leading MIGS Therapies
U.S. RESEARCH ROUNDUP-Avepoint, Meta, United Therapeutics
Glaukos Corp reports results for the quarter ended March 31 - Earnings Summary
Brief: Glaukos Q1 Sales USD 106.7 Million Vs. IBES Estimate USD 102.5 Million
U.S. RESEARCH ROUNDUP- CNB Financial, Disney, Triumph Group